DEMEROL 75 MG/ML 75 MG / 1 ML
MEPERIDINE HYDROCHLORIDE : 75 MG / 1 ML · DIN 02242004 · HOSPIRA HEALTHCARE ULC
Health Canada status: CANCELLED POST MARKET
What is DEMEROL 75 MG/ML?
DEMEROL 75 MG/ML 75 MG / 1 ML contains MEPERIDINE HYDROCHLORIDE : 75 MG / 1 ML. It is listed in the Health Canada Drug Product Database under DIN 02242004, held by HOSPIRA HEALTHCARE ULC, supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 25-Oct-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DEMEROL 75 MG/ML used for?
Demerol is indicated for the relief of acute episodes of moderate to severe pain. Demerol is not indicated as an as-needed (prn) analgesic and should not be used for treatment of chronic pain.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02242004 |
|---|---|
| Brand name | DEMEROL 75 MG/ML |
| Generic / active ingredient | MEPERIDINE HYDROCHLORIDE : 75 MG / 1 ML |
| Manufacturer | HOSPIRA HEALTHCARE ULC |
| Strength | 75 MG / 1 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AB02 PETHIDINE |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 25-Oct-2018 |
| Original market date | 2000-12-01 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02242004 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2242004 |
| Brand name | DEMEROL 75 MG/ML |
| Active ingredient / INN | MEPERIDINE HYDROCHLORIDE : 75 MG / 1 ML |
| ATC code | N02AB02 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02 |
| AHFS class | 28:08.08 |
| Health Canada schedule | NARCOTICS (CDSA I) |
| Biosimilar biologic | No |
| Market authorization holder | HOSPIRA HEALTHCARE ULC |
How is it administered?
Individualized dosing; for acute moderate to severe pain. Adults: IM, IV, or SC. Not for chronic pain. Use lowest effective dose for shortest duration.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
null
Which pack is which?
| Strength on the label | 75 MG / 1 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS ; INTRAVENOUS ; INTRAMUSCULAR |
| Packaging as described in the monograph | null |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Contraindications
Hypersensitivity to meperidine; GI obstruction; acute asthma/COPD; respiratory depression; acute alcoholism; convulsive disorders; head injury; use of MAO inhibitors within 14 days.
Warnings and precautions
Risk of addiction, abuse, misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; risks with concomitant use of benzodiazepines or alcohol.
What can be used instead?
Other Canadian products sharing ATC code N02AB02 PETHIDINE. 1 of 21 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MEPERIDINE HYDROCHLORIDE INJECTION USP | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00725765 |
| DEMEROL | 50 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 02138018 |
| DEMEROL 10%-LIQ IM IV SC | 100 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02139030 |
| DEMEROL 10%-LIQ IM SC 100MG/ML | 100 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02139715 |
| DEMEROL 100 MG/ML | 100 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 02242006 |
| DEMEROL 100 MG/ML | 100 MG / 1 ML | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 02242005 |
| DEMEROL 50 MG/ML (MULTIPLE DOSE WITH METACRESOL AS PRESERVATIVE) | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 02242002 |
| DEMEROL 50 MG/ML (SINGLE USE, PRESERVATIVE FREE) | 50 MG / 1 ML | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 02242003 |
| DEMEROL 50MG - LIQ IM IV SC 50MG/ML | 50 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02139022 |
| DEMEROL 50MG - LIQ IM SC 50MG/ML | 50 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02137992 |
Who else supplies PETHIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PETHIDINE appears in 23 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does PETHIDINE cost around the world?
PETHIDINE is listed on 3 national price registers Nexara tracks, across 11 pack listings published on 3 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 6 | 6 | 01 Sep 2026 |
| United Kingdom | hospital | 3 | 3 | 31 Aug 2026 |
| Saudi Arabia | public | 1 | 2 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.